Newron Pharmaceuticals S.p.A. (SWX:NWRN)
Switzerland · Delayed Price · Currency is CHF 7.98
-0.20 (-2.44%)
Oct 2, 2026, 2:08 PM CET
Newron Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Newron Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of CHF 47.87. The average 1-year stock price forecast is 499.87% higher than the current stock price, while the lowest is CHF 36.10 (+352.38%) and the highest is CHF 73.09 (+815.91%).
Price Target: CHF 47.87 (+499.87%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Newron Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates CHF 44.00 | Buy | Reiterates | CHF 44.00 | +451.38% | Sep 3, 2026 |
Financial Forecast
Revenue This Year
8.49M
from 19.13M
Decreased by -55.62%
Revenue Next Year
39.86M
from 8.49M
Increased by 369.68%
EPS This Year
-1.31
from -0.66
EPS Next Year
0.35
from -1.31
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.